ABSTRACT

Background

BIRC5 is associated with the prognosis of a variety of tumors. This meta-analysis aimed to identify whether BIRC5 is associated with the prognosis of lung adenocarcinoma (LUAD).

Research Design and Methods

We conducted an in-depth review of seven Chinese and English databases and two high-throughput sequencing databases according to inclusion and exclusion criteria to find relevant studies. The pooled standardized mean differences (SMDs) and 95% confidence intervals (CIs) for the associations between the BIRC5 expression level and clinicopathological characteristics were calculated, and the pooled hazard ratios (HRs) and 95% CIs were calculated to estimate associations between the BIRC5 expression level and survival outcomes.

Results

In total, 17 studies involving 2887 LUAD patients whose BIRC5 expression level was known were included in this meta-analysis. The BIRC5 expression level was higher in younger patients, males, and smokers and correlated with advanced AJCC, T and N stages but not M stage. A high BIRC5 expression level also correlated with poor overall survival (OS) and progression-free survival (PFS). There was no publication bias in this study.

Conclusions

This meta-analysis indicates that BIRC5 is a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with LUAD.

中文翻译：

---

含有 5 表达的杆状病毒 IAP 重复序列作为肺腺癌新生物标志物的预后价值：荟萃分析

摘要

背景

BIRC5与多种肿瘤的预后相关。这项荟萃分析旨在确定 BIRC5 是否与肺腺癌 (LUAD) 的预后相关。

研究设计和方法

我们根据纳入和排除标准对7个中英文数据库和2个高通量测序数据库进行了深入回顾，以寻找相关研究。计算了 BIRC5 表达水平与临床病理学特征之间关联的汇总标准化平均差 (SMDs) 和 95% 置信区间 (CIs)，计算汇总风险比 (HRs) 和 95% CI 以估计 BIRC5 之间的关联表达水平和生存结果。

结果

该荟萃分析共纳入 17 项研究，涉及 2887 名已知 BIRC5 表达水平的 LUAD 患者。年轻患者、男性和吸烟者的 BIRC5 表达水平较高，并且与晚期 AJCC、T 和 N 期相关，但与 M 期无关。高 BIRC5 表达水平也与较差的总生存期 (OS) 和无进展生存期 (PFS) 相关。本研究不存在发表偏倚。

结论

这项荟萃分析表明，BIRC5 是 LUAD 患者预后不良和临床病理学结果不佳的重要生物标志物。